Microbot Medical

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees. The company has raised a total of $90.52 million across 15 funding rounds from 2 investors. In September 2025, the company received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

Business overview

Microbot Medical specializes in transformational robotic technologies, primarily focusing on the endovascular space. Its core product, the LIBERTY Robotic System, is designed as the world’s first single-use endovascular robotic system, aiming to increase access to robotic technology and revolutionize endovascular procedures. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry and providers with solutions in robotics, endoscopy, and minimally-invasive procedures.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System. This regulatory approval is a significant validation of the company's technology and signals a critical step towards commercialization, enhancing its market position and potential for widespread adoption in endovascular procedures.

Company Intelligence Q&A

What was a key regulatory milestone for Microbot Medical in 2025?

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, a crucial step for its commercialization.

What was a significant financial event for Microbot Medical in October 2025?

In October 2025, Microbot Medical announced the final closing of the exercise of outstanding preferred investment options, generating up to $92.2 million in gross proceeds.

What was a notable strategic partnership for Microbot Medical in October 2025?

In October 2025, Microbot Medical secured a U.S.-based logistics partner to support the commercialization of its LIBERTY Endovascular Robotic System.

What was a significant product debut for Microbot Medical in November 2025?

In November 2025, Microbot Medical commenced the limited market release of its LIBERTY Endovascular Robotic System in the U.S.

Which institution was the first to adopt Microbot Medical's new robotic system?

In November 2025, Emory University Hospital became the first hospital globally to adopt Microbot Medical's new LIBERTY Endovascular Robotic System.